Vancomycin Treatment of Infective Endocarditis Is Linked with Recently Acquired Obesity

Franck Thuny1,2, Hervé Richet1, Jean-Paul Casalta3, Emmanouil Angelakis1, Gilbert Habib2, Didier Raoult1,3*

1 Unite´ de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, Universite´ de la Me´diterrane´e, Marseille, France, 2 Service de Cardiologie, Hôpital de la Timone, Marseille, France, 3 Pôle de Maladies Infectieuses, Hôpital de la Timone, Marseille, France

Abstract

**Background:** Gut microbiota play a major role in digestion and energy conversion of nutrients. Antibiotics, such as avoparcin (a vancomycin analogue), and probiotics, such as *Lactobacillus* species, have been used to increase weight in farm animals. We tested the effect of antibiotics given for infective endocarditis (IE) on weight gain (WG).

**Methodology/Principal Findings:** Forty-eight adults with a definite diagnosis of bacterial IE (antibiotic group) were compared with forty-eight age-matched controls without IE. Their body mass index (BMI) was collected at one month before the first symptoms and one year after hospital discharge. The BMI increased significantly and strongly in vancomycin-plus-gentamycin–treated patients (mean [±SE] kg/m², +2.3 [0.9], p = 0.03), but not in controls or in patients treated with other antibiotics. Seventeen patients had a BMI increase of ≥10%, and five of the antibiotic group developed obesity. The treatment by vancomycin-plus-gentamycin was an independent predictor of BMI increase of ≥10% (adjusted OR, 6.7; 95% CI, 1.37–33.0; p = 0.02), but not treatment with other antibiotics. Weight gain was particularly high in male patients older than 65 who did not undergo cardiac surgery. Indeed, all three vancomycin-treated patients with these characteristics developed obesity.

**Conclusions/Significance:** A major and significant weight gain can occur after a six-week intravenous treatment by vancomycin plus gentamycin for IE with a risk of obesity, especially in males older than 65 who have not undergone surgery. We speculate on the role of the gut colonization by *Lactobacillus* sp, a microorganism intrinsically resistant to vancomycin, used as a growth promoter in animals, and found at a high concentration in the feces of obese patients. Thus, nutritional programs and weight follow-up should be utilized in patients under such treatment.

Introduction

The prevalence of obesity is a major world health problem that is rapidly increasing in developing countries [1,2]. Currently, more than half of the US population is overweight [3,4] and thus exposed to a high cardiovascular risk. Obesity results from a mixture of genetic background and environmental factors, including food availability, social networks [5], high fat diet, and physical inactivity [6,7]. Recent evidence suggests that gut microbiota play a major role in the digestion an energy conversion of nutrients [8,9].

Moreover, metagenomics studies have demonstrated that the gut microbiota composition may be altered by environmental modifications [10] and differs in lean vs. obese animals and humans [11,12], suggesting its potential role in the pathogenesis of obesity [13,14]. A recent 16S rRNA sequencing-based investigation showed that *Firmicutes* are increased in obese mammals [15]. Additionally, a large body of experimental evidence and empirical data from the food industry has shown that *Firmicutes* probiotics (e.g., *Lactobacillus* and *Enterococcus*) and antibiotics that modify the gut microbiota can act as growth promoters, increasing the size and weight of animals [16,17,18]. Moreover, we recently found that *Lactobacillus* was significantly increased in the stools of obese patients [19]. Avoparcin, an analogue of vancomycin, has been largely used in farm animals [20] and is active on most *Firmicutes*, with the notable exception of *Lactobacillus* species.

Similar growth effects have been observed in children with the long-term use of tetracycline [21], and a possible link between increased antibiotic use and obesity has been proposed [22]. The mechanisms by which antibiotics improve growth performance are not well known, and the selection of gut microorganisms with potential growth promoting effects is one of hypotheses [14,23]. *Lactobacillus* species are thought to be growth promoters, with an intrinsic vancomycin-resistance [24,25] and a probiotic activity [26,27]. Their presence has been shown to dramatically increase food conversion and weight increase in chickens [28], and some reports suggest similar effects in children [29].

Taking advantage of a large cohort of patients treated for infective endocarditis (IE) in our center over many years, we sought to determine the impact of antibiotic therapy, given during...
a long period at high doses levels, on body weight changes. We retrospectively compared the body mass index (BMI) changes of patients one month before the occurrence of the first symptoms compatible with IE and one year after hospital discharge for a group of patients treated for definite IE and a control group.

Methods

Ethics Statement
Written informed consent was obtained from all participating patients and approved by the institutional review board (Comité d’Ethique de l’IFR 48) under reference 08-002.

Patients
We conducted a retrospective analysis in consecutive adults referred for a suspicion of IE to the Department of Cardiology of La Timone Hospital, Marseille, France, from January 2002 to December 2007. A structured, standardized questionnaire was used to collect demographic, clinical, biological, microbiological, echocardiographic, and therapeutic data in all of these patients. The modified Duke criteria [30] were applied to all suspected cases, which were characterized as definite, probable, or excluded. The weight, height, and BMI (weight [Kg]/height$^2$ [m$^2$]) of each patient were collected at two different times, one month before the first symptoms (baseline) and one year after discharge, during systematic and standardized consultations or phone contacts. Finally, we included two groups of patients. The “Antibiotic group” was formed by patients who were definitely diagnosed with bacterial IE and treated by intravenous antibiotics for at least four weeks. We defined the control group (same sample size) as consecutives patients first suspected to have IE but finally receiving an excluded diagnosis. Controls did not receive antibiotics for more than fifteen days. The exclusion criteria were: the absence of weight or height data at baseline or at one year, all conditions (IE more than fifteen days. The exclusion criteria were: the absence of an excluded diagnosis. Controls did not receive antibiotics for consecutives patients first suspected to have IE but finally receiving a long period at high doses levels, on body weight changes. We defined the control group (same sample size) as

Finally, we included two groups of patients. The “Antibiotic group” was formed by patients who were definitely diagnosed with bacterial IE and treated by intravenous antibiotics for at least four weeks. We defined the control group (same sample size) as consecutives patients first suspected to have IE but finally receiving an excluded diagnosis. Controls did not receive antibiotics for more than fifteen days. The exclusion criteria were: the absence of weight or height data at baseline or at one year, all conditions (IE more than fifteen days. The exclusion criteria were: the absence of an excluded diagnosis. Controls did not receive antibiotics for consecutives patients first suspected to have IE but finally receiving a long period at high doses levels, on body weight changes. We defined the control group (same sample size) as

Statistical Analysis

The modified Duke criteria [30] were applied to all suspected cases, which were characterized as definite, probable, or excluded. The weight, height, and BMI (weight [Kg]/height$^2$ [m$^2$]) of each patient were collected at two different times, one month before the first symptoms (baseline) and one year after discharge, during systematic and standardized consultations or phone contacts. Finally, we included two groups of patients. The “Antibiotic group” was formed by patients who were definitely diagnosed with bacterial IE and treated by intravenous antibiotics for at least four weeks. We defined the control group (same sample size) as consecutives patients first suspected to have IE but finally receiving an excluded diagnosis. Controls did not receive antibiotics for more than fifteen days. The exclusion criteria were: the absence of weight or height data at baseline or at one year, all conditions (IE more than fifteen days. The exclusion criteria were: the absence of an excluded diagnosis. Controls did not receive antibiotics for consecutives patients first suspected to have IE but finally receiving a long period at high doses levels, on body weight changes. We defined the control group (same sample size) as

Statistical Analysis

The baseline BMI was that obtained one month before the first symptoms. The changes of BMI at one year were compared between the two groups, and we tested the potential role of the different antibiotics used. Proportions were compared using the Chi-squared test or the Fisher’s exact test. For the continuous variables, the Wilcoxon test and Mann-Whitney test were used for comparison between the two groups. Logistic regression was used to determine the predictors of an increase of BMI ≥10% at one year. The following variables were tested as potential predictors: age, sex, cancer, chronic renal insufficiency, the Charlson comorbidity index [33], stroke, heart failure, cardiac surgery within the year after admission, and the type of antibiotic used in association with gentamycin (i.e., vancomycin, amoxicillin, or other antibiotics). P<0.05 was considered significant, and a Bonferroni’s correction was used in case of multiple comparisons. All statistical analyses were performed using EpInfo software version 3.4.1 (Centers for Disease Control and Prevention, Atlanta, GA, USA).

Results

Patient Characteristics
During the period of study, 2,533 patients were referred for a suspicion of IE. Among them, 48 patients with definite IE fulfilled the inclusion criteria, had no exclusion criterion, and were thus included in the “Antibiotic group”. The control group was then formed by another 48 consecutive patients that received an excluded diagnosis of IE and did not meet the study’s exclusion criterion.

The clinical characteristics of the two groups are summarized in the Tables 1 and 2. The weight and BMI one month before the first symptoms (baseline) did not differ significantly between the two groups (Antibiotic vs. Control group; weight [Kg], 75.2±17 vs. 69.8±15, p=0.10; BMI [Kg/m$^2$], 25.3±5 vs. 23.9±4, p=0.14). No significant difference was observed between the two groups in terms of age, sex, diabetes, chronic renal insufficiency, comorbidity index, previous heart disease, presence of prosthetic valve, history of heart failure, or smoking behavior. However, a history of cancer was more frequently noticed in the Antibiotic group (20.8% vs. 4.2%, p=0.03), and a cardiac surgery within one year after admission was also performed more frequently in the Antibiotic group (72.9% vs. 16.7%, p<0.0001).

In the Antibiotic group, 28 patients received amoxicillin for four to six weeks in association with gentamycin for six, four, three, or two weeks in five, three, three, or 17 patients, respectively. Eleven patients received vancomycin for four to six weeks in association with gentamycin for six, two, or one weeks in six, three, or eight patients, respectively. Nine patients received other antibiotics.

BMI Changes

The BMI increased significantly in the Antibiotic group (mean [±SE] Kg/m$^2$, +1.1 [0.5], p=0.02) but not in the controls (mean [±SE] Kg/m$^2$, −0.2 [0.2], p=0.38). After stratification according to the type of antibiotics, BMI significantly and strongly increased only after treatment by vancomycin+gentamycin (mean [±SE] Kg/m$^2$, +2.3 [0.9], p=0.03) (Figure 1). No significant BMI increase was observed with amoxicillin+gentamycin or the other antibiotics. Seventeen patients had a BMI increase of ≥10%: 16 (33.3%) in the Antibiotic group and only one (2.1%) in the control group (p<0.0001). This major increase of BMI was observed at a rate of 63.4% after treatment with vancomycin+gentamycin, 25% after treatment with amoxicillin+gentamycin, and 22.2% after treatment with other antibiotics (p<0.0001). The rate of BMI increase ≥10% was significantly higher after vancomycin+gentamycin treatment than in controls (p<0.0001) or after a treatment by amoxicillin+gentamycin (p=0.02) or other antibiotics (p=0.06) (Figure 2). Among all 96 patients assessed, five developed obesity.
defined as a new BMI $> 30$ Kg/m² after an increase of their BMI $\geq 10\%$. Three of those had been treated with vancomycin + gentamycin and two with amoxicillin + gentamycin.

After multivariable analysis, treatment with vancomycin + gentamycin remained the only predictor of a major increase of BMI (adjusted OR, 6.7; 95% CI, 1.37–33.0; $p = 0.02$) (Table 3).

By stratified analysis, the impact of vancomycin on the risk of increased BMI $\geq 10\%$ was particularly high in males ($p = 0.06$), in patients older than 65 ($p = 0.01$), and in the absence of cardiac surgery ($p = 0.03$) (Figure 3). Three patients in the study were males, older than 65, and underwent vancomycin treatment without surgery. All of them became obese after a BMI increase $\geq 10\%$, with a weight increase of 20 Kg, 17 Kg, and 10 Kg, respectively.

No significant difference in lifestyle was noticed according the different groups.

**Discussion**

The main result of the present work shows a significant and persistent weight gain after an episode of IE in patients who had been treated by vancomycin and gentamyci.

Antibiotics promote weight gain and were among the first growth promoters used in agriculture. Indeed, avoparcin, a glycopeptide structurally related to vancomycin, was widely used in Europe as a growth promoter from the early 1970s until a recent ban due to the emergence of vancomycin-resistant enterococci [20]. This antibiotic has been shown to improve feed efficiency and increases weight gain (WG) in animals [34]. Moreover, previous studies have demonstrated that the use of antibiotics in humans, especially in infants and children, is also associated with WG [21]. The mechanism by which antibacterial agents improve growth performance is not well known, but several hypotheses have been proposed [16]: (i) nutrients are more efficiently absorbed because of a thinner small-intestinal epithelium; (ii) nutrients are spared because competing microorganisms are reduced; (iii) microorganisms responsible for subclinical infections are reduced or eliminated; (iv) production of growth-depressing toxins or metabolites by intestinal microflora is reduced; or (v) modifications of bacterial enzyme activity improve food efficiency. Thus, there is increasing evidence about the role of the gut’s microorganisms on the energy conversion of nutrients [8] and their implications on obesity. This has been supported by reports involving mouse models with a genetic tendency for obesity [9,13,15]. A recent 16S rRNA sequencing-based investigation

---

**Table 1.** Clinical characteristics of patients in the Antibiotic and control groups.

|                                | Antibiotic group | Controls | $p$ value |
|--------------------------------|------------------|----------|-----------|
| **Age, mean ±SD, y**           | 59.5 ± 14        | 63.2 ± 14| 0.20      |
| **Male**                       | 36 (75)          | 29 (60.4)| 0.13      |
| **Baseline* weight, mean ±SD, Kg** | 75.2 ± 17        | 69.8 ± 15| 0.10      |
| **Baseline* BMI, mean ±SD, Kg/m²** | 25.3 ± 5         | 23.9 ± 4 | 0.14      |
| **Diabetes**                   | 2 (4.2)          | 1 (2.1)  | 1.0       |
| **Cancer**                     | 10 (20.8)        | 2 (4.2)  | 0.03      |
| **Chronic renal insufficiency** | 3 (6.3)          | 1 (2.1)  | 0.62      |
| **Previous heart disease**     | 33 (68.8)        | 37 (77.1)| 0.36      |
| **Prosthetic valve**           | 14 (29.2)        | 18 (37.5)| 0.39      |
| **Pacemaker, implantable cardioverter defibrillator** | 11 (22.9)     | 5 (10.4) | 0.10      |
| **Stroke**                     | 5 (10.4)         | 0 (0)    | 0.06      |
| **Heart failure**              | 19 (39.6)        | 19 (39.6)| 1.0       |
| **Quit smoking**               | 1 (2.5)          | 1 (2.5)  | 1.0       |
| **Cardiac surgery with the year after admission** | 35 (72.9) | 8 (16.7) | <0.0001   |

Values are number (%).  
BMI = body mass index.  
*Baseline is defined as one month before the first symptoms.  
1Defined as yes if smokers reported that they had quit smoking since the previous period. Data available in 40 patients.  
doi:10.1371/journal.pone.0009074.t001

**Table 2.** Causes of hospitalization in the 48 controls.

|                                | n     |
|--------------------------------|-------|
| Unexplained fever in patients with heart valve disease or PPM or ICD | 15    |
| Fever related to an acute degenerative mitral chordae rupture | 7     |
| Respiratory tract infection | 7     |
| Pericarditis, myocarditis | 4     |
| Paraprostatic leak without IE | 5     |
| PPM or ICD local pocket infection | 2     |
| Local catheter related infection in patient with heart valve disease | 2     |
| Stroke | 1     |
| Chronic lymphoid leukemia | 1     |
| Urinary tract infection in patient with heart valve disease | 1     |
| Systemic lupus | 1     |
| Fever related to neuroleptic treatment | 1     |
| Myxoma | 1     |
| PPM = pacemaker; ICD = implantable cardioverter defibrillator.  
doi:10.1371/journal.pone.0009074.t002
showed that the Firmicutes/Bacteroidetes ratio differed in obese and lean mammals, mainly due to an increased Firmicutes proportion in obese mammals [15]. Lactobacillus sp, one of these bacterial communities with probiotic activity, has an impact on food conversion and a potential effect on WG, as demonstrated in farm animals [26,27,28]. Lactobacillus sp treatment results in higher metabolic activity, lower levels of non-esterified fatty acids, triglycerides, urea, and an increase in the levels of alkaline phosphatase and creatine kinase [35]. Vendt et al. treated 120 healthy infants (up to two months), with either regular formula, or formula supplemented with $10^7$ CFU/g L. rhamnosus strain GG. After six months, the 51 children that received the Lactobacillus-supplemented formula gained weight more rapidly and displayed significantly greater body length and weight than those receiving the regular formula [29].

These well known data concerning the impact of avoparcin and Lactobacillus sp on WG in animals and humans may explain the results found with vancomycin in the present study. Indeed, vancomycin is an analogue of avoparcin, and Lactobacillus sp are
known to be resistant to glycopeptides [24,25]. Thus, we can speculate that the weight gain was induced by the growth promoter effect of *Lactobacillus* sp in patients who had been treated by vancomycin. Moreover, a previous study in rats demonstrated that amoxicillin induced alterations in microbial populations that included depletion of the *Lactobacillus* sp [36]. These results are in accordance with the absence of significant weight gain observed in our patients treated with amoxicillin.

The empirical data from agriculture and experimental data in laboratory animals show that manipulating gut microbiota by antibiotic administration or by colonization with selected bacteria results in significant WG. We speculate that some antibiotics and probiotics may have the same effect in humans. A recent study shows that one cause of an abrupt shift in intestinal microbiota in babies is antibiotic treatment [10]. Thus, a possible link between increased antibiotic use and obesity has been recently proposed [22,37], and our preliminary results add credence to this hypothesis.

Moreover, our stratified analysis showed the impact of three factors that could influence weight changes during antibiotic treatment: cardiac surgery, age, and gender. First, cardiac surgery could have limited the WG in some patients because of a longer hospitalization, especially in intensive care units where the calorific intake is not optimal. Second, the fact that older patients had a greater WG may be explained by a higher proportion of treatment without surgery in this subgroup. Finally, the trend towards a greater WG in males could be either related to the fact that females pay more attention to their weight changes than males in our country [38] or to the relatively small sample size of females in the present work.

It should be noted that the present study has several limitations, including the small sample size and the absence of a systematic, prospectively collected questionnaire of lifestyle. However, with our eligibility criteria, the profile of patients in the two groups was similar because it represents the relatively homogenous sample of those in whom IE was suspected. Moreover, the history of cancer that was more frequently noticed in the Antibiotic group emphasizes the results on weight gain observed in that group.

Finally, our hypothesis about the colonization of the gut by *Lactobacillus* sp in patients treated with vancomycin is at this time only speculative and needs to be confirmed. We are currently testing this hypothesis.

### Table 3. Predictors of an increase of BMI \( \geq 10\% \).

| Predictor                        | OR     | 95% CI      | \( p \)  | Adjusted OR | 95% CI | \( p \)  |
|---------------------------------|--------|-------------|---------|-------------|--------|---------|
| Age                             | 1.0    | 0.96–1.04   | 0.68    |             |        |         |
| Male sex                        | 3.2    | 0.61–16.7   | 0.17    |             |        |         |
| Cancer                          | 0.8    | 0.18–3.73   | 0.80    |             |        |         |
| Chronic renal insufficiency     | 1.0    | 0.08–11.9   | 1.0     |             |        |         |
| Comorbidity index \( \geq 2 \) | 1.3    | 0.38–4.65   | 0.67    |             |        |         |
| Stroke                          | 0.6    | 0.06–5.58   | 0.62    |             |        |         |
| Heart failure                   | 0.2    | 0.23–0.06   | 0.05    | 0.2         | 0.04–1.0 | 0.05   |
| Cardiac surgery                 | 0.7    | 0.20–2.76   | 0.65    |             |        |         |
| Vancomycin+gentamicyn           | 5.4    | 1.29–23.0   | 0.02    | 6.7         | 1.37–33.0 | 0.02   |
| Other antibiotics               | 2.1    | 0.27–16.8   | 0.47    |             |        |         |
| Amoxicillin+gentamicyn          | 0.4    | 0.12–1.39   | 0.15    |             |        |         |

Figure 3. Impact of vancomycin treatment on the risk of major increase of body mass index (BMI \( \geq 10\% \)) in patients treated for infective endocarditis according to age, gender, and cardiac surgery. doi:10.1371/journal.pone.0009074.g003
Conclusion
Significant and persistent WG can occur after treatment with high doses of vancomycin in patients with IE. The risk of obesity is particularly high in vancomycin-treated male patients older than 65 who did not undergo cardiac surgery. If these results are confirmed by other studies, it will be important to prevent major WG, possible obesity, and all of their associated consequences after a long treatment with antibiotics. Hence, we suggest nutritional programs and weight follow-up in patients undergoing such treatment, especially those with a history of heart disease. Finally, we hypothesize that the growth promoter effect of vancomycin might be explained by the selection of Lactobacillus sp in the gut microbial flora.

Acknowledgments
The authors thank Dr Frédérique Gouriet for her participation in the study.

Author Contributions
Conceived and designed the experiments: JPC DR. Performed the experiments: FT EA. Analyzed the data: FT HR DR. Contributed reagents/materials/analysis tools: FT GH. Wrote the paper: FT.

References
1. Flegal KM, Carroll MD, Ogden CL, Johnson CL (2002) Prevalence and trends in obesity among US adults, 1999–2000. JAMA 288: 1723–1727.
2. Eckel RH, York DA, Rosner S, Hubbard V, Caterson I, et al. (2004) Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: executive summary. Circulation 110: 2968–2973.
3. Hill JO, Wyatt HR, Reed GW, Peters JC (2003) Obesity and the environment: where do we go from here? Science 299: 853–855.
4. Ogden CL, Yanovski SZ, Carroll KM, Flegal KM (2007) The epidemiology of obesity. Gastroenterology 132: 2067–2102.
5. Christakis NA, Fowler JH (2007) The spread of obesity in a large social network over 32 years. N Engl J Med 357: 370–379.
6. Hill JO, Peters JC (1996) Environmental contributions to the obesity epidemic. Science 280: 1371–1374.
7. Friedman JM (2009) Obesity: causes and control of excess body fat. Nature 459: 340–342.
8. Backlund F, Ding H, Wang T, Hooper LV, Kod GY, et al. (2004) The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 101: 15718–15723.
9. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, et al. (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444: 1027–1031.
10. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO (2007) Development of the human infant intestinal microbiota. PLoS Biol 5: e177.
11. Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, et al. (2006) Metagenomic analysis of the human distal gut microbiome. Science 312: 1355–1359.
12. DiBaise JK, Zhang H, Crowell MD, Krajmalnik-Brown R, Decker GA, et al. (2008) Gut microbiota and its possible relationship with obesity. Mayo Clin Proc 83: 469–469.
13. Ley RE, Turnbaugh PJ, Klein S, Gordon JJ (2006) Microbial ecology: human gut microbes and associated obesity. Nature 442: 1022–1023.
14. Raoult D (2008) Obesity pandemics and the modification of digestive bacterial flora. Eur J Clin Microbiol Infect Dis 27: 631–654.
15. Samuel BS, Gordon JJ (2006) A humanized gnotobiotic mouse model of host-archaeal-bacterial mutualism. Proc Natl Acad Sci U S A 103: 10011–10016.
16. Feighner SD, Dadakova MP (1987) Subtherapeutic levels of antibiotics in poultry feeds and their effects on weight gain, feed efficiency, and bacterial enteric-malabsorption-malnutrition: the potential of limited studies. Neonatal antibiotic treatment alters gastrointestinal tract developmental gene expression and intestinal barrier transcriptome. Physiol Genomics 23: 235–245.
17. Ternak G (2005) Antibiotics may act as growth/obesity promoters in humans as animal growth promoters: a plea for science in decision-making. Clin Microbiol Infect 6: 477–482.
18. Nevala JS, Sexton DJ, Mikk N, Netter P, Fowler VG Jr, et al. (2006) Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 50: 633–638.
19. Botelho-Nevers E, Thuny F, Casalta JP, Richet H, Gouriet F, et al. (2009) Dramatic reduction in infective endocarditis-related mortality with a management-based approach. Arch Intern Med 169: 1290–1298.
20. Condon RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, et al. (2006) ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society for Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 48: e1–148.
21. Charlton ME, Pompei P, Ales KL, Mackenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373–383.
22. Dyer IA, Koes RM, Herlageon ML, Ojikatu LB, Preston RL, et al. (1980) Effect of avoparcin and monensin on performance of finishing heifers. J Anim Sci 57: 2838–2846.
23. Raoult D (2008) Human microbiome: take-home lesson on growth promoters? Nature 454: 690–691.
24. Delgado S, Florez AB, Mayo B (2005) Antibiotic susceptibility of Lactobacillus and bifidobacterium species from the human gastrointestinal tract. Curr Microbiol 50: 202–207.
25. Ammer MS, Florez AB, Mayo B (2007) Antibiotic resistance in non-enterococcal lactic acid bacteria and bifidobacteria. Food Microbiol 24: 559–570.
26. Timmerman RM, Mulder L, Events H, van Esen DC, van der Wal E, et al. (2005) Health and growth of veal calves fed milk replacers with or without probiotics. J Dairy Sci 88: 2135–2166.
27. Abe F, Ishibashi N, Shimamura S (1995) Effect of administration of bifidobacteria and lactic acid bacteria to newborn calves and piglets. J Dairy Sci 78: 2030–2046.
28. Khan M, Raoult D, Richet H, Lepidi H, La Scola B (2007) Growth-promoting effects of single-dose intragastrically administered probiotics in chickens. Br Poult Sci 48: 732–735.
29. Vendt N, Grunberg H, Tuure T, Malinuenei O, Wuolijoki E, et al. (2006) Growth during the first 6 months of life in infants using formula enriched with Lactobacillus rhamnosus GG: double-blind, randomized trial. J Hum Nutr Diet 19: 51–58.
30. Li JS, Sexton DJ, Mikk N, Netter P, Fowler VG Jr, et al. (2006) Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 50: 633–638.
31. Boletto-Nevers E, Thuny F, Casalta JP, Richet H, Gouriet F, et al. (2009) Dramatic reduction in infective endocarditis-related mortality with a management-based approach. Arch Intern Med 169: 1290–1298.
32. Condon RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, et al. (2006) ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society for Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 48: e1–148.
33. Charlton ME, Pompei P, Ales KL, Mackenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373–383.
34. Dyer IA, Koes RM, Herlageon ML, Ojikatu LB, Preston RL, et al. (1980) Effect of avoparcin and monensin on performance of finishing heifers. J Anim Sci 57: 2838–2846.
35. Chioda P, Liotta L, Chioda B (2004) Effects of the administration of Lactobacilli on body growth and on the metabolic profile in growing Maltese goat kids. Reprod Nutr Dev 44: 449–457.
36. Schumann A, Nutten S, Domicola D, Comelli EM, Mansourian R, et al. (2005) Neonatal antibiotic treatment alters gastrointestinal tract developmental gene expression and intestinal barrier transcriptome. Physiol Genomics 23: 235–245.
37. Ternak G (2005) Antibiotics may act as growth/obesity promoters in humans as animal growth promoters: a plea for science in decision-making. Clin Microbiol Infect 6: 477–482.
38. Chioda P, Liotta L, Chioda B (2004) Effects of the administration of Lactobacilli on body growth and on the metabolic profile in growing Maltese goat kids. Reprod Nutr Dev 44: 449–457.
39. Schumann A, Nutten S, Domicola D, Comelli EM, Mansourian R, et al. (2005) Neonatal antibiotic treatment alters gastrointestinal tract developmental gene expression and intestinal barrier transcriptome. Physiol Genomics 23: 235–245.
40. Ternak G (2005) Antibiotics may act as growth/obesity promoters in humans as animal growth promoters: a plea for science in decision-making. Clin Microbiol Infect 6: 477–482.